Related Experiment Video
Updated: Feb 8, 2026

Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
Integrin, alpha9 subunit blockade suppresses collagen-induced arthritis with minimal systemic immunomodulation
Shingo Sugahara1, Kaori Hanaoka1, Nobuchika Yamamoto1
1Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
Abstract:
Integrin, alpha9 subunit (hereinafter, alpha9) has been identified as a novel putative therapeutic target for rheumatoid arthritis (RA). Support for this target comes from the observations that alpha9 is overexpressed both in the joints of RA patients and in animal models of arthritis. In the experimental models, the increase in alpha9 expression precedes the onset of arthritic symptoms. The current study presents data on the pharmacological profile of an anti-alpha9 antibody in a collagen-induced arthritis (CIA) mouse model. Administration of an alpha9-blocking antibody in CIA mice suppressed the development of arthritis and significantly decreased plasma level of activated fibroblast-like synoviocyte (FLS)-derived biomarkers without reducing the formation of anti-type II collagen antibodies. While anti-alpha9 antibody administration significantly suppress the accumulation of immune cells in arthritic joints it had no effect on immune cell number in the spleen. Furthermore, in non-arthritic mice, alpha9 had no inhibitory effect in either a mixed lymphocyte reaction (MLR) or in a delayed type hypersensitivity (DTH) reaction. These results suggest that blocking alpha9 exerts its anti-arthritic effect through suppression of FLS-activation via a non-immune mediated mechanism. Finally, therapeutic administration of anti-alpha9 antibody alleviated established arthritis in CIA mice. Our data provide evidence that alpha9 blockade is a promising therapy for joint inflammation with minimal systemic immunomodulation.
Insights
Blocking alpha9, a novel target for rheumatoid arthritis (RA), suppressed arthritis development in mice by reducing fibroblast-like synoviocyte activation. This approach shows promise for joint inflammation therapy with minimal immune system impact.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Integrin, alpha9 subunit (alpha9) is overexpressed in rheumatoid arthritis (RA) joints and preclinical models, preceding symptom onset.
- Alpha9 is identified as a novel therapeutic target for RA due to its elevated expression in affected tissues.
Purpose of the Study:
- To evaluate the pharmacological profile of an anti-alpha9 antibody in a collagen-induced arthritis (CIA) mouse model.
- To investigate the mechanism of action for alpha9 blockade in arthritis, focusing on fibroblast-like synoviocyte (FLS) activation and immune responses.
Main Methods:
- Administration of an anti-alpha9 antibody in CIA mice.
- Assessment of arthritis development, plasma biomarkers, antibody formation, and immune cell populations in joints and spleen.
- Evaluation of alpha9's role in mixed lymphocyte reaction (MLR) and delayed type hypersensitivity (DTH) in non-arthritic mice.
Main Results:
- Anti-alpha9 antibody treatment suppressed arthritis development and decreased FLS-derived biomarkers in CIA mice.
- Alpha9 blockade reduced immune cell accumulation in arthritic joints but not in the spleen.
- No inhibitory effect of alpha9 blockade was observed in MLR or DTH reactions in non-arthritic mice.
- Therapeutic administration of anti-alpha9 antibody alleviated established arthritis.
Conclusions:
- Alpha9 blockade exerts anti-arthritic effects by suppressing FLS activation through a non-immune mediated mechanism.
- Targeting alpha9 offers a promising therapeutic strategy for joint inflammation in RA with minimal systemic immunomodulation.
- Anti-alpha9 therapy is effective in both preventing and treating established arthritis in a preclinical model.
More Related Videos
11:03A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
Published on: October 30, 2019
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Related Concept Videos
Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Neuromuscular Junction And Blockade
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...